In an interview with PharmaShots, Salomé Juethner, Senior Medical Director, Rare Diseases at Takeda shared her views on the P-III HELP study of Takhzyro for the prevention of hereditary angioedema […]readmore
Tags : Takhzyro
Shots: The P-III HELP OLE study evaluates the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged ≥12yrs. with HAE attacks for ~2.5yrs. Results: 87.4% mean reduction in […]readmore
Shots: The P-III HELP OLE study evaluating the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged ≥12yrs. with HAE attacks for ~2.5 yrs. Results: 87.4% mean reduction […]readmore
Shots: The positive recommendation is based on P-III Help Study Open-label Extension assessing Takhzyro (300mg, q2w) in 212 HAE adolescents and adults aged ≥12 yrs. The P-III Help study OLE […]readmore
Shots: The P-III HELP (Hereditary Angioedema Long-term Prophylaxis) study involves assessing of Takhzyro (300/150 mg, SC) (lanadelumab) vs PBO in 125 patients with HAE attacks for 26 weeks aged 12 […]readmore
Shots: The approval is based on P-III HELP study results assessing Takhzyro (300 mg q2w, 300 mg q4w, 150 mg q4w) vs PBO in 125 patients with HAE aged ≥12 […]readmore
Shots: Approval is based on four clinical studies including P-III HELP (Hereditary Angioedema Long-term Prophylaxis) study (N=125) for 26 wks, administering Takhzyro 300mg Q2W, Q4W and 150 mg Q4W HELP […]readmore